Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Investment Income (2016 - 2023)

Ironwood Pharmaceuticals (IRWD) has disclosed Non Operating Investment Income for 9 consecutive years, with $19000.0 as the latest value for Q1 2023.

  • Quarterly Non Operating Investment Income fell 97.4% to $19000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $19000.0 through Dec 2023, down 89.56% year-over-year, with the annual reading at $19000.0 for FY2023, 89.56% down from the prior year.
  • Non Operating Investment Income hit $19000.0 in Q1 2023 for Ironwood Pharmaceuticals, up from -$18000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $4.5 million in Q4 2019 to a low of -$4.8 million in Q3 2019.
  • Historically, Non Operating Investment Income has averaged -$240176.5 across 5 years, with a median of -$18000.0 in 2022.
  • Biggest five-year swings in Non Operating Investment Income: skyrocketed 199.7% in 2019 and later plummeted 710.95% in 2021.
  • Year by year, Non Operating Investment Income stood at $4.5 million in 2019, then plummeted by 90.7% to $420000.0 in 2020, then tumbled by 710.95% to -$2.6 million in 2021, then soared by 99.3% to -$18000.0 in 2022, then soared by 205.56% to $19000.0 in 2023.
  • Business Quant data shows Non Operating Investment Income for IRWD at $19000.0 in Q1 2023, -$18000.0 in Q4 2022, and $151000.0 in Q3 2022.